Inventor
BOISSEL LAURENT H
US24 patents
⚠️ This page may combine multiple inventors who share the name “BOISSEL LAURENT H”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
IMMUNITYBIO INC
13 patentsUS11547727B2Jan 10, 2023
Chimeric antigen receptor-modified NK-92 cells
IMMUNITYBIO INC10 citations85
US11643452B2May 9, 2023
Fc-epsilon car
IMMUNITYBIO INC6 citations83
US12473347B2Nov 18, 2025
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
IMMUNITYBIO INC1 citations73
US12473348B2Nov 18, 2025
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
IMMUNITYBIO INC1 citations73
US12403178B2Sep 2, 2025
Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)
IMMUNITYBIO INC2 citations73
US12109238B2Oct 8, 2024
Chimeric antigen receptor-modified NK-92 cells
IMMUNITYBIO INC2 citations73
US12435122B2Oct 7, 2025
Fc-epsilon CAR
IMMUNITYBIO INC3 citations72
US11813292B2Nov 14, 2023
Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity)
IMMUNITYBIO INC2 citations71
US12378300B2Aug 5, 2025
Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells
IMMUNITYBIO INC1 citations64
US12365874B2Jul 22, 2025
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
IMMUNITYBIO INC1 citations64
US12180283B2Dec 31, 2024
Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
IMMUNITYBIO INC1 citations62
US11992504B2May 28, 2024
Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
IMMUNITYBIO INC0 citations62
US12584138B2Mar 24, 2026
Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
IMMUNITYBIO INC0 citations61
NANTKWEST INC
7 patentsUS11077143B2Aug 3, 2021
Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
NANTKWEST INC16 citations93
US10960024B2Mar 30, 2021
Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
NANTKWEST INC17 citations93
US11230699B2Jan 25, 2022
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
NANTKWEST INC9 citations85
US10765701B2Sep 8, 2020
Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells
NANTKWEST INC7 citations84
US11129850B2Sep 28, 2021
Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
NANTKWEST INC8 citations82
US11058723B2Jul 13, 2021
Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies
NANTKWEST INC8 citations82
US12498363B2Dec 16, 2025
Combined invasion and cytotoxicity assay using chemokine secreting target cells
NANTKWEST INC0 citations56